IBK Investment & Securities projected on the 2nd that the expansion of the overseas distribution network for Dongkoo Pharmaceutical's cosmetics brand 'Centellian24' will drive earnings growth.

Dongkoo Pharmaceutical operates over-the-counter (OTC) drugs such as Madecassol and Insadol, ethical drugs (ETC) centered on generics, and a cosmetics business, broadening its business scope.

The focus of this analysis is the expansion of Centellian24's overseas sales base. IBK Investment & Securities expects that growth in the cosmetics business through the expansion of overseas distribution networks will contribute to Dongkoo Pharmaceutical's earnings.

Going forward, how much the expansion of overseas distribution networks translates into actual revenue growth will be a key point of interest in gauging the growth trajectory of the cosmetics business.

[This article was written based on the securities firm's analysis provided and does not constitute an investment recommendation. Earnings forecasts may vary depending on market and business conditions, and investment decisions and responsibilities rest with the investor. This article was written with the assistance of AI.]